Gomari et al. confirmed that exosomal delivery of doxorubicin to HER2 + BC was very effective, with decreased cancer proliferation [27], while Melzer et al. reported that the transport of paclitaxel through MSC-originated exosomes is very effective in BC cells inducing a 90% augmentation in cell toxicity respect to the usual treatment [28]. Here, ERBB2 is linked to cancer.